3.67

5.66% -0.22

After Hours: 3.67

Precigen Inc (PGEN)

Overview News Price History Option Chain Financials Discussions Forecast

Precigen Inc stock is traded at $3.67, with a volume of 7.06M. It is down -5.66% in the last 24 hours and down -3.17% over the past month. Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Previous Close:

$3.89

Open:

$3.8

24h Volume:

7.06M

Relative Volume:

1.58

Market Cap:

$1.30B

Revenue:

$9.68M

Net Income/Loss:

$-250.64M

P/E Ratio:

-2.6218

EPS:

-1.3998

Net Cash Flow:

$-89.83M

1W Performance:

+11.89%

1M Performance:

-3.17%

6M Performance:

+4.56%

1Y Performance:

+123.78%

1-Day Range:

$3.62

$4.00

1-Week Range:

$3.04

$4.275

52-Week Range:

$1.11

$5.465

Precigen Inc Stock (PGEN) Company Profile

Name

Precigen Inc

Sector

Healthcare (1112)

Industry

Biotechnology (620)

Phone

301-556-9900

Address

20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD

Employee

Twitter

@precigen

Next Earnings Date

2026-03-25

Latest SEC Filings

PGEN's Discussions on Twitter

Compare PGEN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PGEN Precigen Inc	3.67	1.38B	9.68M	-250.64M	-89.83M	-1.3998
VRTX Vertex Pharmaceuticals Inc	433.07	115.27B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	737.71	80.00B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	691.40	43.00B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	317.36	43.52B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	283.03	30.74B	5.36B	287.73M	924.18M	2.5229

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight
Feb-25-21	Initiated	Stifel	Buy
Feb-22-21	Initiated	Wells Fargo	Overweight
Feb-18-21	Initiated	B. Riley Securities	Buy
May-08-20	Initiated	H.C. Wainwright	Buy

View All

Precigen Inc Stock (PGEN) Latest News

08:00 AM

HC Wainwright Has Positive Estimate for Precigen Q3 Earnings - MarketBeat

08:00 AM

07:35 AM

Discover Precigen And 2 Other Insider-Favored Growth Stocks - Yahoo Finance

07:35 AM

01:06 AM

Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge? - Yahoo Finance

01:06 AM

Mar 26, 2026

Precigen Earnings Call Signals Powerful Launch Momentum - TipRanks

Mar 26, 2026

Analyst Upgrade: Whats the beta of Precigen Inc stockMarket Weekly Review & Fast Gain Stock Tips - baoquankhu1.vn

Mar 26, 2026

Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has) - Seeking Alpha

Mar 26, 2026

These Analysts Boost Their Forecasts On Precigen Following Q4 Results - Benzinga

Mar 26, 2026

Precigen (PGEN) Soars 26% Despite Missed Revenue Estimates - GuruFocus

Mar 26, 2026

Precigen (NASDAQ:PGEN) Shares Gap Up Following Analyst Upgrade - MarketBeat

Mar 26, 2026

Precigen (PGEN) Shares Surge on Positive Q1 Outlook Despite Earnings Miss - GuruFocus

Mar 26, 2026

Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday - Benzinga

Mar 26, 2026

Precigen (NASDAQ:PGEN) Price Target Raised to $9.00 at Citizens Jmp - MarketBeat

Mar 26, 2026

H.C. Wainwright raises Precigen stock price target on sales growth By Investing.com - Investing.com India

Mar 26, 2026

Precigen (NASDAQ:PGEN) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Mar 26, 2026

Precigen, Inc. (NASDAQ:PGEN) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 26, 2026

H.C. Wainwright raises Precigen stock price target on sales growth - Investing.com

Mar 26, 2026

Precigen (PGEN) Reports Strong Q4 2025 with PAPZIMEOS Launch - GuruFocus

Mar 26, 2026

Citizens raises Precigen stock price target on strong PAPZIMEOS sales By Investing.com - Investing.com Australia

Mar 26, 2026

Citizens raises Precigen stock price target on strong PAPZIMEOS sales - Investing.com

Mar 26, 2026

Precigen Achieves First Commercial Revenue in 2025 with FDA Approval and Strong US Launch of PAPZIMEOS for RRP - Minichart

Mar 26, 2026

Precigen Inc. 2025 Annual Report: Papzimeos Launch, UltraCAR-T & AdenoVerse Platform, Clinical Pipeline, Risks, and Competitive Landscape 33 34 35 38 40 54 - Minichart

Mar 26, 2026

Beyond the Balance Sheet: What SWOT Reveals About Precigen Inc (PGEN) - GuruFocus

Mar 26, 2026